tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2015-3-18-23tumors-148Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL REPORTSПериоперационная химиотерапия немелкоклеточного рака легкого: проблемы и пути решенияPerioperative chemotherapy for non-small-cell lung carcinoma: problems and solutionsСАКАЕВАД. Д.SAKAEVAD. D.

д. м.н., заместитель главного врача по химиотерапии

Doctor of Medical Sciences, Deputy Chief Physician in chemotherapy

d_sakaeva@mail.ruГУЗ Республиканский клинический онкологический диспансер Минздрава Республики Башкортостан, г. УфаРоссияRepublican Clinical Oncological Health Center of Republic of Bashkortostan Ministry of HealthRussian Federation201526102015031823Copyright © САКАЕВА Д.Д., 20152015САКАЕВА Д.Д.SAKAEVA D.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/148

Рак легкого (РЛ) является наиболее часто встречающейся злокачественной опухолью и ведущей причиной смертности, обусловленной онкологическими заболеваниями по всему миру. Частота летальных исходов вследствие РЛ сопоставима с совокупной частотой случаев смерти от опухолей предстательной железы, толстой кишки и поджелудочной железы [10].Около 85% этих опухолей являются немелкоклеточным раком легкого (НМРЛ). Хотя операция рассматривается как оптимальное лечение, только в 25–30% случаев опухоли потенциально резектабельны. 5-летняя выживаемость после оперативного вмешательства для патологической Ia стадии НМРЛ составляет до  3%, и 25% для патологической IIIa стадии [3]. Только 31% — 40% пациентов, нуждающихся в проведении адъювантной химиотерапии (АХТ), получают это лечение [5].

Lung cancer (LC) is the most frequent malignant tumor and leading cause of death among oncological diseases worldwide. Mortality due to lung cancer is comparable with cumulative mortality due to prostate, colon and pancreatic cancer [10]. About 85% cases of LC are non-small-cell lung carcinoma (NSCLC). Although the operation is considered as the optimal treatment, only 25–30% cases of these tumors are potentially resectable. Five-year survival after surgical treatment for stage IA of NSCLC is 73% and for stage IIIA — is 25% [3]. Only 31–40% of patients who need adjuvant treatment receive it [5].

немелкоклеточный рак легкогоадъювантная химиотерапиянеоадъювантная химиотерапияnon-small cell lung canceradjuvant chemotherapyneoadjuvant chemotherapyReferencesAdjuvant chemotherapy for non-small-cell lung cancer in the elderly: a population-based study in Ontario, Canada.J Clin Oncol. 2012 May 20;30(15):1813–21. Epub 2012 Apr 23.Adjuvant chemotherapy for non-small-cell lung cancer in the elderly: a population-based study in Ontario, Canada.J Clin Oncol. 2012 May 20;30(15):1813–21. Epub 2012 Apr 23.Ardizzoni A., Tiseo M., Boni L. et al. CISCA (cisplatin vs. carboplatin) metaanalysis: An individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) // J. Clin. Oncol. — 2006. — Vol.24. — P. 366s.Ardizzoni A., Tiseo M., Boni L. et al. CISCA (cisplatin vs. carboplatin) metaanalysis: An individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) // J. Clin. Oncol. — 2006. — Vol.24. — P. 366s.Besse B., Le Chevalier T. Developments in the treatment of early NSCLC: when to use chemotherapy//Annals of Oncology. —2012–23 –V 23(10). — p.52–59.Besse B., Le Chevalier T. Developments in the treatment of early NSCLC: when to use chemotherapy//Annals of Oncology. —2012–23 –V 23(10). — p.52–59.Booth C. M., Shepherd F. A., Peng Y. et al. Adoption of adjuvant chemotherapy for non’small cell lung cancer: a population based outcomes study // J. Clin. Oncol. — 2010. — Vol.28(15s): part I, abstract 7018.Booth C. M., Shepherd F. A., Peng Y. et al. Adoption of adjuvant chemotherapy for non’small cell lung cancer: a population based outcomes study // J. Clin. Oncol. — 2010. — Vol.28(15s): part I, abstract 7018.Bray FI, Weiderpass E. Lung cancer mortality trends in 36 European countries: secular trends and birth cohort patterns by sex and region 1970–2007 // Int. J. Cancer. — 2009. — Vol.126. — P. 1454–1466.Bray FI, Weiderpass E. Lung cancer mortality trends in 36 European countries: secular trends and birth cohort patterns by sex and region 1970–2007 // Int. J. Cancer. — 2009. — Vol.126. — P. 1454–1466.Burdett S, Stewart La, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 2006;1:611–621.Burdett S, Stewart La, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 2006;1:611–621.Capeletti M., Wang X. F., Gu L. et al. Impact of KRAS mutation on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB9633 // Proc. ASCO. — 2010, J. Clin. Oncol. — 2010. —Vol.28(15s): part I, abstract 7008.Capeletti M., Wang X. F., Gu L. et al. Impact of KRAS mutation on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB9633 // Proc. ASCO. — 2010, J. Clin. Oncol. — 2010. —Vol.28(15s): part I, abstract 7008.Gilligan D, Nicolson M, Smith I et al Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVaLT 2/ EORTC08012 multicentre randomised trial and update of systematic review. Lancet2007;369:1929–1937.Gilligan D, Nicolson M, Smith I et al Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVaLT 2/ EORTC08012 multicentre randomised trial and update of systematic review. Lancet2007;369:1929–1937.Imyanitov E. N., Moiseyenko V. M. Molecular_based choice of cancer therapy: realities and expectations // Clin. Chim.Acta. — 2007 (Apr). — Vol.379(1–2). — P. 1–13.Imyanitov E. N., Moiseyenko V. M. Molecular_based choice of cancer therapy: realities and expectations // Clin. Chim.Acta. — 2007 (Apr). — Vol.379(1–2). — P. 1–13.Jemal A., Bray F., Center M. M. et al. Global cancer statistics // J. CA Cancer Clin. — 2011. — Vol.61. — P. 69–90.Jemal A., Bray F., Center M. M. et al. Global cancer statistics // J. CA Cancer Clin. — 2011. — Vol.61. — P. 69–90.Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non–Small-Cell Lung Cancer J Clin Oncol. 2012;30(2):172–178.Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non–Small-Cell Lung Cancer J Clin Oncol. 2012;30(2):172–178.Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small cell lung cancer [published online ahead of print November 28, 2011]. J Clin Oncol. 2012;30(2):172–178.Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small cell lung cancer [published online ahead of print November 28, 2011]. J Clin Oncol. 2012;30(2):172–178.Song Wa, Zhou NK, Wang W, et al.Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials. J Thorac Oncol 2010;5:510–516.Song Wa, Zhou NK, Wang W, et al.Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials. J Thorac Oncol 2010;5:510–516.Westeel V., Milleron B. J., Quoix E. A. et al. Long’term results of the French randomized trial comparing neoadjuvant chemotherapy followed by surgery versus surgery alone in resectable non-small cell lung cancer // Proc. ASCO. — 2010, J. Clin. Oncol. — 2010. — Vol.28(15s): part I, abstract 7003.Westeel V., Milleron B. J., Quoix E. A. et al. Long’term results of the French randomized trial comparing neoadjuvant chemotherapy followed by surgery versus surgery alone in resectable non-small cell lung cancer // Proc. ASCO. — 2010, J. Clin. Oncol. — 2010. — Vol.28(15s): part I, abstract 7003.Westeel V, Quoix E, Puyraveau M, Lavole A, Braun D, Laporte S, et al. A randomised trial comparing preoperative to perioperative chemotherapy in earlystage non-small-cell lung cancer (IFCT 0002 trial). Eur J Cancer. 2013;49(12):2654–2664.Westeel V, Quoix E, Puyraveau M, Lavole A, Braun D, Laporte S, et al. A randomised trial comparing preoperative to perioperative chemotherapy in earlystage non-small-cell lung cancer (IFCT 0002 trial). Eur J Cancer. 2013;49(12):2654–2664.Winton T., Livingston R., Johnson D. et al. Vinorelbine plus cisplatin vs.observation in resected non-small cell lung cancer // N. Engl. J. Med. — 2005. — Vol.352. — P. 2589–2597.Winton T., Livingston R., Johnson D. et al. Vinorelbine plus cisplatin vs.observation in resected non-small cell lung cancer // N. Engl. J. Med. — 2005. — Vol.352. — P. 2589–2597.Zojwalla N. J., Raftopoulos H., Gralla R. Are cisplatin and carboplatin equivalent in the treatment of nonsmall cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients // J. Clin. Oncol. — 2004. — Vol.22. — 633s.Zojwalla N. J., Raftopoulos H., Gralla R. Are cisplatin and carboplatin equivalent in the treatment of nonsmall cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients // J. Clin. Oncol. — 2004. — Vol.22. — 633s.

The authors declare that there are no conflicts of interest present.